News & Updates

Subcutaneous amivantamab compares favourably with intravenous dosing in EGFR-mutant NSCLC
Subcutaneous amivantamab compares favourably with intravenous dosing in EGFR-mutant NSCLC
18 Jun 2024 byJairia Dela Cruz

In previously treated patients with EGFR-mutated advanced non-small-cell lung cancer (NSCLC), subcutaneous (SC) amivantamab combined with lazertinib shows noninferior pharmacokinetic and efficacy profiles compared with the approved intravenous (IV) formulation of amivantamab, according to the phase III PALOMA-3 trial.

Subcutaneous amivantamab compares favourably with intravenous dosing in EGFR-mutant NSCLC
18 Jun 2024
NMR helps tailor treatment for smoking cessation in smokers with COPD
NMR helps tailor treatment for smoking cessation in smokers with COPD
18 Jun 2024

Among smokers with chronic obstructive pulmonary disease (COPD), use of varenicline seems better than bupropion in normal metabolizers, but bupropion displays similar efficacy and less side effects in slow metabolizers, reports a study.

NMR helps tailor treatment for smoking cessation in smokers with COPD
18 Jun 2024
Nivolumab plus chemo offers prolonged survival in resectable NSCLC
Nivolumab plus chemo offers prolonged survival in resectable NSCLC
14 Jun 2024 byStephen Padilla

Patients with resectable nonsmall cell lung cancer (NSCLC) enjoy sustained survival from neoadjuvant nivolumab when added to chemotherapy compared with chemotherapy alone, as seen in the 4-year analysis from the phase III CheckMate 816 study.

Nivolumab plus chemo offers prolonged survival in resectable NSCLC
14 Jun 2024